



45th ISOBM

(International Society of Oncology & BioMarkers)

2018 CONGRESS

HAMBURG, NOVEMBER 24-27, 2018

Tumor diagnosis and therapy - role of Biomarkers



ISOBM 2018 CONGRESS

CONGRESS PRESIDENT - BARAK V

ORGANIZING COMMITTEE

BARAK V	(ISRAEL)	HOLDENRIEDER S	(GERMANY)
CHECHLINSKA M	(POLAND)	KLAPDOR R	(GERMANY)
DIAMANDIS E	(CANADA)	MOLINA R	(SPAIN)
DUFFY J	(IRELAND)	MORO R	(CANADA)
ECKE T	(GERMANY)	NICOLINI A	(ITALY)

SCIENTIFIC COMMITTEE

ANDRIOLO A	(Brazil)	MOLINA R	(Spain)
ARLEN P	(USA)	MORO R	(Canada)
BARAK V	(Israel)	NAP M	(Holland)
CHECHLINSKA M	(Poland)	NICOLINI A	(Italy)
DELINASIOS JG	(Greece)	PANTEL K	(Germany)
DIAMANDIS E	(Canada)	SELL S	(USA)
DUFFY J	(Ireland)	STIEBER P	(Germany)
ECKE T	(Germany)	STIGBRAND T	(Sweden)
FRITSCH H	(USA)	TOPOLCAN O	(Czech Rep.)
HOLDENRIEDER S	(Germany)	ROMAGNANI S	(Italy)
KINKOROVA J	(Czech Rep.)	YARDEN Y	(Israel)
KLAPDOR R	(Germany)	ZIMA T	(Czech Rep.)
LAMERZ R	(Germany)		

Dear colleagues, dear participants,

On behalf of the Board and the Congress Organizing Committee of the
ISOBM - International Society of Oncology and Biomarkers -

I am pleased to invite you to actively participate in the

45th ISOBM Congress

Hamburg, Germany, November 24 - 27, 2018.

Our Theme - Tumor Diagnosis and Therapy - Role of Biomarkers


The 2018 Congress has the aim to bring together participants active in all fields of basic and clinical research in Oncology, in order to optimize clinical results in cancer prevention, diagnosis and therapy.

More than before, Biomarkers hold out promise for improving the outcome of cancer patients by optimization of diagnostic procedures, in combination with clinical parameters and various imaging methods. By continuous development of standardization, quality control and automatization, as well as by applying new individualized targeted treatments, we succeed now to improve patients state and survival. The new therapeutic agents can be combined with the established chemo-radiotherapy of Cancer disease.

Relevant new findings in research, diagnosis and clinical Oncology - as well as technical developments, standardization and quality control, will be presented by Opinion Leaders in Oral and Poster presentations, along with panel discussions. In addition, as during recent years, the EGTM (European Group of Tumor Markers) will present their Guidelines on optimal use of Tumor Markers and their clinical interpretation.

Hamburg is a beautiful metropolis in the northern part of Europe and Germany, well-known for sightseeing in the center with the Alster and the Elbe and for social events, shopping, dining, museums of art and science/ history. In addition, the congress time in November will also allow the participants to enjoy the first days of the well-known Christmas Markets in the city of Hamburg. Please allow us to look forward to host you at the ISOBM Congress in Hamburg, November 2018, to exchange ideas and expertise in an International forum and to enjoy the hospitality of Hamburg.

Prof. Vivian Barak



ISOBM 2018

		FRIDAY, 23.11.18	SATURDAY, 24.11.18
--	--	------------------	--------------------

TIME	TIME		Hall A	Hall B
08:30 - 10:30	2h	ISOBM BOARD (14-18)	Cancers	xxxxxx
10:30 - 11:00	0.5h		Coffee, posters, exhibition	
11:00 - 13:00	2h		Prostate Ca 1	Liquid Biopsy
13:00 - 13:45	3/4h		LUNCH	
13:45 - 14:30	3/4h		Key Note ABBOTT Award	
14:30 - 16:30	2h		Bladder Ca	GSEV
16:30 - 17:00	0.5h	REGISTRATION	Coffee, posters, exhibition	
17:00 - 19:00	2h		Bladder Ca	INSTAND
19:30				
		OPENING CEREMONY		
		WELLCOME PARTY		

PROGRAM

SUNDAY, 25.11.18		MONDAY, 26.11.18		TUESDAY, 27.11.18	
Hall A	Hall B	Hall A	Hall B	Hall A	Hall B
Breast Ca	ENT	Immunotherapy	Pancreatic Ca	Prostate Ca 2	Lung Ca
Coffee, posters, exhibition					
Breast Ca	New Therap	Immunotherapy	Pancreatic Ca	BioBanking	Lung Ca
LUNCH					
Key Note		Key Note		Key Note	
Ovarian Ca	CESAR	CRC	Melanoma	Lymphoma	xxxxxxx
Coffee, posters, exhibition					
Ovarian Ca	EGTM	CRC	POSTERS	Closing ceremony- Awards 16:00-16:30	
			BOARD 17:00-18:30		
	EGTM	GALA Dinner			
	Dinner				

KEY NOTE LECTURES

HALL A , 13:45-14:30

24.11.18 YARDEN Y, PhD (ISRAEL)

ABBOTT AWARD

Chair, Department of Biological Regulation,
Director, Dwek Institute for Cancer Therapy Research
Weizmann Institute of Science, Rehovot.

HER-2 and EGFR: Molecular mechanisms and roles in Cancer treatments

25.11.18 PANTEL K, PhD (GERMANY)

Head, Institute of Tumor Biology, University of Hamburg, Hamburg

Clinical applications of Circulating Tumor Cells as liquid biopsy in Cancer patients

26.11.18 KAGAN J, PhD (USA)

Program Director, Cancer Biomarkers Research Group
Division of Cancer Prevention, National Cancer Institute, NIH.

Spatial and Temporal Tumor Atlas - a new approach for development of Cancer Biomarkers and targets for prevention and therapy

27.11.18 LETOURNEAU C, MD, PhD (FRANCE)

Head, Department of Drug Development and Innovation, Institute Curie,
Paris & Saint-Cloud

Precision Medicine in Oncology

SESSION: CANCER DETECTION and MONITORING

CHAIRS: FRITSCHÉ H (USA) DIAMANDIS E (CANADA)

08:30-09:00 DUFFY MJ, PhD (IRELAND)

Clinical Research Center, St Vincent's University Hospital and School of Medicine, University College Dublin, Dublin

Cancer Screening: does it always decrease mortality

09:00-09:30 DIAMANDIS EP, MD, PhD, FRCP(C), FRSC, (CANADA)

Hold'em for Life Chair in Prostate Cancer Biomarkers,
Head, Division of Clinical Biochemistry, Mount Sinai Hospital and University Health Network, Department of Laboratory Medicine & Pathobiology, University of Toronto

Personalized Cancer Biomarkers

09:30-10:00 GION M, MD (ITALY)

Director, Regional Center for Cancer Biomarkers, Venice
Editor in Chief, The International Journal of Biological Markers

State of the art and trends in the clinical use of Cancer Biomarkers

10:00-10:30 LOOIJENGA L, PhD (HOLLAND)

Pathology Dep., Erasmus MC, Rotterdam, Zuid Holland.

(Epi) Genetic heterogeneity of human Germ Cell Cancers: clinical implications

10:30-11:00 COFFEE, POSTERS, EXHIBITION

SESSION: NEW PERSPECTIVES in DIAGNOSIS and THERAPY of PROSTATE CANCER 1

CHAIRS: ROOBOL M (HOLLAND) KAGAN J, PhD (USA)

11:00-11:30 ROOBOL MJ, MD, PhD (HOLLAND)

Decision Making in Urology, Erasmus MC, University Medical Center, Rotterdam

Biomarkers, imaging and clinical data: the combination is the key

11:30-12:00 KAGAN J, PhD (USA)

Program Director, Cancer Biomarkers Research Group

Division of Cancer Prevention, National Cancer Institute, NIH.

Verification of Prostate Cancer Genomic biomarkers at the Protein Level using SRM-MS.

12:00-12:30 KULKARNI H, PhD (GERMANY)

Molecular Radiotherapy, Central Hospital, Bad Berka.

Personalized Molecular Radiotherapy of Neuroendocrine Tumors and Prostate Cancer: THERANOSTICS for Precision Oncology

12:30-13:00 MEIROVITZ A, MD (ISRAEL)

Head, Focused & Stereotactic Radiotherapy Unit,

Hadassah Medical Center, Jerusalem

A modern approach to locally advanced Prostate Cancer

13:00-13:45 LUNCH

KEY NOTE - ABBOTT AWARD LECTURE

13:45 - 14:30 YARDEN Y, PhD (ISRAEL)

Chair, Department of Biological Regulation, Director, Dwek Institute for Cancer Therapy Research, Weizmann Institute of Science, Rehovot.

HER - 2 and EGFR: Molecular mechanisms and roles in Cancer treatments

SESSION: LIQUID BIOPSY

CHAIRS: CHECHLINSKA M (POLAND) HOLDENRIEDER S (GERMANY)

- 11:00-11:30** **HOLDENRIEDER S, MD (GERMANY)**
Head, Institute of Laboratory Medicine, German Heart Center, Technical University, Munich
Liquid Biopsy and Precision Medicine - Hype or Hope?
- 11:30-12:00** **DIEHL F, PhD (GERMANY)**
CEO Sysmex-Inostics GmbH, Hamburg
Cell-free tumor DNA testing: From clinical trials to clinical practice
- 12:00-12:30** **WINTER C, MD, PhD (GERMANY)**
Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich
Prognostic and predictive relevance of RNA profiles in Prostate Cancer
- 12:30-13:00** **BRONKHORST A, PhD (GERMANY)**
Institute of Laboratory Medicine, German Heart Center, Technical University Munich
Biology and release of circulating nucleic acids into plasma and serum
- 13:00-13:45** **LUNCH**

SESSION: BLADDER CANCER

CHAIRS: ECKE T (GERMANY) SANCHEZ-CARBAYO M (SPAIN)

- | | |
|--------------------|---|
| 14:30-14:45 | ECKE T, MD (GERMANY)
Urology Clinic, HELIOS Hospital, Bad Saarow.
Urinary based Tumor Markers in Bladder Cancer |
| 14:45-15:00 | ROGGISCH J, M.Sc (GERMANY)
Institute of Pathology, HELIOS Hospital Bad Saarow, Germany
Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in invasive and non-invasive urothelial Bladder Cancer |
| 15:00-15:30 | KILTIE A, PhD (UK)
Senior Clinical Group Leader/Honorary Consultant Clinical Oncologist CRUK/MRC Oxford Institute for Radiation Oncology, Oxford
Predictive Biomarkers of radiotherapy response in Bladder Cancer |
| 15:30-16:00 | van RHIJN B, MD, PhD, FEBU (HOLLAND)
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Molecular Markers (FGFR3 mutation; p53 & Ki-67 expression) and Clinical Outcome of Radical Cystectomy for Bladder Cancer: A Multi-center, Multi-lab Study |
| 16:00-16:15 | GOLKA K, PhD (GERMANY)
Leibniz Research Centre for Working Environment and Human Factors, Dortmund.
Interplay of four genetic high-risk variants for Urinary Bladder Cancer |
| 16:15-16:30 | RABIEN A, PhD (GERMANY)
Department of Urology, University Hospital Charité, Berlin.
Drosha and the Argonautes 1 and 2 as Potential Biomarkers for Urothelial Bladder Carcinoma: an Immunohistochemical Study |
| 16:30-17:00 | COFFEE, POSTERS, EXHIBITION |

SESSION: EXTRACELLULAR VESICLES, GSEV

CHAIRS: KRAMER-ALBERS EM, PhD (GERMANY)

14:30-15:00 HENDRIX A, PhD (GERMANY)

Head, Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, University Gent

Standardized analysis of extracellular vesicles in liquid biopsies

15:00-15:30 NAZARENKO I, PhD (GERMANY)

Head, Exosomes and Tumor Biology Group, Institute of Prevention of Infections and Hospital Hygenics, University Hospital Freiburg

New devices in nanotechnology for detection of extracellular vesicles in liquid biopsy

15:30-16:00 KAHLERT C, MD (GERMANY)

Head, Exosome Research Group, Department of Visceral, Thoracic and Vascular Surgery, University Hospital Dresden

Evaluation of circulating exosomes as diagnostic marker in Pancreatic Cancer

16:00-16:30 PFAFFL M, PhD (GERMANY)

Chair, Department of Animal Physiology & Immunology, Life Science Center Weihenstephan, Technical University Munich

Exosomal microRNA biomarkers signatures in clinical diagnostics

16:30- 17:00 COFFEE, POSTERS, EXHIBITION

SESSION: BLADDER CANCER

CHAIRS: ECKE T (GERMANY) SANCHEZ-CARBAYO M (SPAIN)

17:00-17:30 **OEHR P, PhD, MPE (JAPAN)**

Honsha, Bio-Med-Pharma, Japan

Joint Assessment of Sensitivity/Specificity Curves (SS-ROC) and positive/negative predictive Values Curves (PV-ROC) Interrelation with Reference to clinical Studies of Bladder Cancer and simulated Pattern Analysis.

17:30-18:00 **NAWROTH R, PhD (GERMANY)**

University Hospital Rechts der Isar, Technical University of Munich

Molecular response mechanisms to CDK4/6 inhibitors in Bladder Cancer involve Skp/Cullin/F-box (SCF) complexes that regulate MDM2 and Rb

18:00-18:30 **MALMSTROM P, PhD (SWEDEN)**


University of Uppsala

UBC Rapid as a Marker for Bladder Cancer

18:30-19:00 **SANCHEZ-CARBAYO M, PhD (SPAIN)**

Faculty of Biological Sciences, Universidad Pontificia de Salamanca

Exploring predictive Biomarkers of BCG response in T1 high grade Bladder Cancer



SESSION: STANDARDIZATION AND QUALITY ASSESSMENT - INSTAND e.V.

CHAIRS: HOLDENRIEDER S, MD (GERMANY) HABERMANN J, MD, PhD (GERMANY)

17:00-17:30 WOJTALEWICZ N, PhD (GERMANY)

INSTAND e.V., Düsseldorf.

Tumor marker EQA trials: Trends and considerations

17:30-18:00 UHLIG S, PhD (GERMANY)


QuoData Quality and Statistics, Dresden, Berlin

New strategies for EQA design and evaluation

18:00-18:30 HABERMANN J, MD, PhD (GERMANY)

Head, Section for Translational Surgical Oncology and Biobanking, Department of Surgery and Director, Interdisciplinary Center for Biobanking-Lübeck (ICB-L), University of Lübeck, President, ESBB (European, Middle Eastern and African Society for Biopreservation and Biobanking)

How can Hospital integrated Biobanks support individualized medicine?



SESSION: BREAST CANCER: EARLY DETECTION, PREDICTION OF RESPONSE, NEW THERAPIES

CHAIRS: HARBECK N (GERMANY) SENKUS E (POLAND)

08:30-09:00 DUFFY J, PhD (IRELAND)

School of Medicine, Clinical Research Centre, St Vincent's University Hospital, Dublin.

Mutant P53 in Breast Cancer: Biology, Biomarker and potential as a therapeutic target

09:00-09:30 HARBECK N, MD, PhD (GERMANY)

Head, Breast Center of Munich University

Individualized Biomarker-based therapy decisions in Early Breast Cancer

09:30-10:00 SENKUS E MD, PhD (POLAND)

Department of Oncology & Radio-therapy,
Medical University of Gdańsk, Poland

ESMO Guidelines for Breast Cancer

10:00-10:30 OED M, PhD (GERMANY)

BIONTECH DIAGNOSTICS

MAMMATYPER- a new innovative molecular in vitro diagnostic tool for Breast Cancer subtyping

10:30-11:00 COFFEE, POSTERS, EXHIBITION

SESSION: ENT CANCERS

CHAIRS: **FRIEDRICH RF (GERMANY)** **MEIROVITZ A (ISRAEL)**

08:30-09:00 **FRIEDRICH RF, MD (GERMANY)**

ENT and Surgical Dep, University Hospital, Hamburg

Oral and maxillofacial tumors- diagnosis and management

09:00-09:30 **MEIROVITZ A, MD (ISRAEL)**

Head, Focused & Stereotactic Radiotherapy Unit,
Hadassah Medical Center, Jerusalem

New Immune therapies for ENT Cancers

09:30-09:45 **FADRUS P, MD, PhD (CZECH REP)**

Department of Neurosurgery, University Hospital Brno, Czech Republic

Prediction potential of selected microRNAs in glioblastoma patients

09:45-10:00 **BARAK V, PhD (ISRAEL)**

Head, Immunology Lab for Tumor Diagnosis,
Hadassah -University Medical Center, Jerusalem.

MUC-13, a new Biomarker

10:00-10:30 **BUENTZEL J, MD (GERMANY)**

ORL, Head and Neck Surgery, Suedharz-Klinikum Nordhausen gGmbH,
Nordhausen.

**Combination of Photodiagnosis (PD) and Photodynamic Therapy (PDT) in
Head Neck Cancer Patients**

10:30-11:00 **COFFEE, POSTERS, EXHIBION**

SESSION: BREAST CANCER: EARLY DETECTION, PREDICTION OF RESPONSE, NEW THERAPIES

CHAIRS: HARBECK N (GERMANY) SENKUS E (POLAND)

11:00- 11:30 : **NICOLINI A, MD (ITALY)**

Unit of Oncology 1, University Hospital of Pisa, Italy.

Serum Tumor Markers in the surveillance of asymptomatic women following surgery for primary Breast Cancer: unsolved questions

11:30- 12:00 : **BARAK V, PhD (ISRAEL)**

Head, Immunology Lab for Tumor Diagnosis, Hadassah-Hebrew University Medical Center, Jerusalem

Assessment of treatment response and early detection of metastases by Tumor Markers in Breast Cancer.

12:00-12:30 : **FOCKE C, PhD (GERMANY)**

Dietrich-Bonhoeffer-Clinic, Neubrandenburg.

Immunohistochemistry vs. m-RNA based intrinsic subtyping of primary Breast Cancer: Influence of the proliferation measurement method on concordance rate.

12:30-12:45 : **BANYS M, PhD (GERMANY)**

Department of Gynecology, Marien Hospital, Hamburg.

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic Breast Cancer

12:45-13:00 : **KARLIKOVA M, MD, PhD (CZECH REP.)**

Department of Immunochemistry, University Hospital and Faculty of Medicine, Plzen

Circulating Matrix Metalloproteinases as Biomarkers in Colorectal and Breast Cancers - a pilot study

13:00 - 13:45 : **LUNCH**

KEY NOTE LECTURE

13:45 - 14:30 : **PANTEL K, PhD (GERMANY)**

Head, Institute of Tumor Biology, University of Hamburg, Hamburg

Clinical applications of Circulating Tumor Cells as liquid biopsy in Cancer patients

SESSION: NEW THERAPIES

CHAIRS: JANKET SJ (USA) KEISARI Y (ISRAEL)

11:00-11:30 KEISARI Y, PhD (ISRAEL)

Clinical Microbiology and Immunology Department, Sackler Faculty of Medicine, Tel Aviv University and Chief Biomedical Officer, Alpha Tau Medical LTD.

Ablation of tumors by a novel alpha-mediated radiotherapy can trigger a curative anti-tumor immunity

11:30-12:00 JANKET SJ, DMD, MPH (USA)

Translational Oral Medicine, Forsyth Institute, Cambridge, MA

Does the microbiome affect the efficacy of cancer immunotherapy?

12:00-12:30 AHMADZADEHFAR H, MD, MSc (GERMANY)

University Hospital, Bonn

Theranostic Applications of Lutetium-177 in Nuclear Oncology

12:30-13:00 HALLENSLEBEN K, PhD (GERMANY)

GEFAT-IT GmbH, Geschäftsleitung IT - Oldendorf.

Flexible and sustainable Data Management for Biobanks

13:00 - 13:45 LUNCH

SESSION: OVARIAN CANCER

CHAIRS: JESCHKE U (GERMANY) ZEIMET AG (AUSTRIA)

- 14:30-15:00** FRITSCHKE H, PhD (USA)
Past, Head of MD Anderson Hospital, Clinical Laboratory
Ovarian Cancer risk assessment in women with pelvic mass disease
- 15:00-15:30** JESCHKE U, MD (GERMANY)
Head, Gynecology Department, Munich University
Expression and Function of Prostaglandin Receptors in Gynecologic Cancer
- 15:30-16:00** ZEIMET AG, MD (AUSTRIA)
Past President of the Austrian AGO, Head, Division of Gynecologic Oncology,
Vice, Head, Department of Gynecology and Obstetrics, Innsbruck Medical
University, Innsbruck
BioMarkers of Endometrium
- 16:00-16:30** KULASINGAM V, PhD (CANADA)
Department of Laboratory Medicine & Pathobiology,
University of Toronto
Using Omics to understand Ovarian Cancer pathogenesis
- 16:30-17:00** COFFEE, POSTERS, EXHIBITION
- 17:00- 17:30** DOBERSTEIN K, PhD (USA)
University of Pennsylvania
L1CAM for detection of Ovarian Cancer
- 17:30-18:00** CHECHLINSKA M, PhD (POLAND)
Head, Department of Immunology, Maria Skłodowska-Curie Memorial Cancer
Center, University of Warsaw
Long non-coding RNAs in Ovarian Cancer

SESSION: TRANSLATIONAL BIOMARKERS APPROACHES - CESAR

CHAIRS: KLOFT C, PhD (GERMANY) RITTER C, PhD (GERMANY)

14:30-15:00 **BENDAS G, PhD (GERMANY)**

Head, Institute of Pharmaceutic Chemistry, University of Bonn

Discovery of drug resistance mechanisms

15:00-15:30 **RITTER C, PhD (GERMANY)**

Head, Institute of Pharmacy, University of Greifswald

The use of systems pharmacology approaches to identify drug resistance networks

15:30-16:00 **KLOFT C, PhD (GERMANY)**

Head, Department of Clinical Pharmacy and Biochemistry,
Free University, Berlin


Mathematic modelling of disease development and drug response

16:00-16:30 **MAYER F, PhD, MD (GERMANY)**

Center for Internal Medicine, Oncology and Hematology, Friedrichshafen.

Individualized drug monitoring in the CEPAC-TDM lung cancer trial

16:30-17:00 **COFFEE, POSTERS, EXHIBITION**



Media Partners

ESO - The European School of Oncology

<https://www.eso.net/>



UICC - Union for international Cancer Control

<https://www.uicc.org/>

EACR - European Association for Cancer Research

<https://www.eacr.org/meeting/isobm-international-society-of-oncology-and-biomarkers-2018-congress>



Cancer Research and Pharmacology



Paediatric Radiation Oncology Society, PROS

PAEDIATRIC RADIATION
ONCOLOGY SOCIETY

IGCS - the International Gynecologic Cancer Society



caro-acro- Oncology in Canada



Cancer Epigenetics Society



EGTM - European Group of Tumor Markers



The Israel Cancer Association



SESSION: EGTM:
(EUROPEAN GROUP of TUMOR MARKERS)

CHAIRS: MOLINA R (SPAIN) BARAK V (ISRAEL)

17:00- 17:30 MOLINA R, MD. PhD (SPAIN)

Head, Clinical Laboratory- OncoBiology Unit, Hospital Clinic,
University of Barcelona

EGTM Lung Cancer Guidelines

17:30-18:00 PUIG S, MD (SPAIN)

Hospital Clinic, University of Barcelona

S-100 in the early diagnosis of Malignant Melanoma relapse

18:00-18:30 BARCO SANCHEZ A, MD (SPAIN)

Unidad de Bioquímica tumoral UGC, Bioquímica Clínica del Hospital
Universitario Virgen Macarena de Sevilla

**HE-4 alone and in combination with IOTA in the diagnosis
of abdominal masses**

EGTM DISCUSSIONS and DINNER



SESSION: IMMUNO THERAPY

CHAIRS: ROMAGNANI S (ITALY) JANKET SJ, (USA)

- 08:30-09:00** JANKET SJ, DMD, MPH (USA)
Translational Oral Medicine, Forsyth Institute, Cambridge, MA
Mechanisms and predictors of the immune Checkpoint Inhibitor therapy failure
- 09:00-09:30** DIAMANDIS EP, MD, PhD, FRCP(C), FRSC, (CANADA)
Hold'em for Life Chair in Prostate Cancer Biomarkers, Head, Division of Clinical Biochemistry, Mount Sinai Hospital and University Health Network, Department of Laboratory Medicine & Pathobiology, University of Toronto
Biomarkers for Cancer Immunotherapy
- 09:30- 10:00** FERRARI P, MD (ITALY)
Unit of Oncology 1, University Hospital of Pisa
Immunotherapy for Breast Cancer
- 10:00-10:30** MORO R, MD (CANADA)
PACIFIC Research Center, Richmond BC
The AFP Receptor (RECAF) as a marker for targeted Cancer therapy
- 10:30-11:00** COFFEE, POSTERS, EXHIBITION
- 11:00-11:15** KRUGER K (GERMANY)
Munich Biomarker Research Center, Institute of Laboratory Medicine, German Heart Center, Technical University Munich
Development and Validation of Novel ELISA Assays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2.
- 11:15-11:30** CREE I, PhD, (UK)
International Agency for Research on Cancer (IARC), WHO
Immunosuppression in Breast Cancer
- 11:30-12:00** ROMAGNANI S, PhD (ITALY)
Immunology Dep, Florence University
Resistance to Immunotherapy in Cancer patients
- 12:00-13:00** ISOBM GA - GENERAL ASSEMBLY
- 13:00-13:45** LUNCH

KEY NOTE LECTURE

- 13:45 - 14:30** KAGAN J, PhD (USA)
Program Director, Cancer Biomarkers Research Group
Division of Cancer Prevention, National Cancer Institute, NIH.
Spatial and Temporal Tumor Atlas - a new approach for development of Cancer Biomarkers and targets for prevention and therapy

SESSION: PANCREATIC CANCER

CHAIRS: K LAPDOR R (GERMANY) IZBICKI JR (GERMANY)

08:30-09:00	<p>BLOCK A, PhD, (GERMANY) Oncology Dep, University Hospital, Hamburg Hereditary Pancreatic Cancer</p>
09:00-09:30	<p>IZBICKI JR, MD (GERMANY) Surgery Dep, University Hospital, Hamburg Actual and future role of resective surgery in a multidisciplinary and sequential concept of Pancreatic Cancer therapy</p>
09:30-10:00	<p>K LAPDOR R, MD (GERMANY) University Hospital, Hamburg Exocrine Pancreatic Cancer- 40 years of clinical experience</p>
10:00-10:30	<p>TANIUCHI K, MD (JAPAN) Gastroenterology and Hepatology, Kochi Medical School, Kochi University. CCDC88A mRNA localizing in circulating tumor-derived exosomes as novel serological marker for Pancreatic Cancer</p>
10:30-11:00	<p>COFFEE, POSTERS, EXHIBITION</p>
11:00-11:30	<p>KRUGER S, MD (GERMANY) Department of Medicine III, University Hospital, LMU Munich. Therapy prediction and monitoring in Pancreatic Cancer by serial KRAS evaluations</p>
11:30-12:00	<p>GERCKENS M (GERMANY) Departement of Internal Medicine III, University Hospital Munich-Grosshadern, Munich, Bavaria. Interleukin-6 and Interleukin-8 predict overall survival in patients with metastatic Pancreatic Cancer</p>
13:00 - 13:45	<p>LUNCH</p>

SESSION: GASTRIC and CRC

CHAIRS: DUFFY M (IRELAND) CREE I (UK)

- 14:30-15:00** CREE I, PhD (UK)
International Agency for Research on Cancer (IARC), World Health Organization (WHO).
Colorectal Cancer detection from blood
- 15:00-15:30** NIELSEN HJ, MD, PhD (DENMARK)
Hvidovre Hospital, Copenhagen
Improved selection to colonoscopy by the triage concept
- 15:30-16:00** CHRISTENSEN I, MD, PhD (DENMARK)
Hvidovre Hospital, Copenhagen
Determination of a multivariable signature for prediction of survival of patients with Colorectal Cancer based on 14 protein biomarkers from 3 cohorts.
- 16:00-16:15** TOPOLCAN O, MD, PhD (CZECH REP)
Head, Biochemical Division, University Hospital and Faculty of Medicine, Plzen.
Biomarkers and Liver Cancer process
- 16:15-16:30** PESTA M, MD (CZECH REP)
Department of Biology, Faculty of Medicine and Charles University, Plzen,
Prognostic significance of circulating microRNAs in patients with Colorectal Cancer
- 16:30 - 17:00** COFFEE, POSTERS, EXHIBITION
- 17:00-17:30** HASELMANN V, MD (GERMANY)
Institute of Clinical Chemistry, University Hospital Mannheim
Liquid profiling of Colorectal Cancer – status quo and future perspectives
- 17:30-17:45** KUCERA R, PhD (CZECH REP)
University Hospital in Plzen and Faculty of Medicine in Plzen.
New Biomarkers and Multivariate Analysis in Gastric Cancer Diagnostics
- 17:45-18:00** FEKETE R, MD (ROMANIA)
Oncology Dep, University of Medicine and Pharmacy, Luliv Hatieganu, Cluj-Napoca
Fluctuations of CEA in the conventional normal range and the risk of relapse in resected CRC
- 18:00-18:30** DUFFY M, PhD (IRELAND)
Clinical Research Center, St Vincent's University Hospital and School of Medicine, University College Dublin, Dublin
Biomarkers in Colorectal Cancer for today and tomorrow:

SESSION: MELANOMA

CHAIRS: **MARKEL G (ISRAEL)** **GEBHARDT C (GERMANY)**

14:30-15:00 **MARKEL G, MD, PhD (ISRAEL)**

Head, Immunotherapy for Melanoma Unit, Sheba Medical Center

Novel therapies for Melanoma patients

15:00-15:30 **GEBHARDT C, MD, PhD (GERMANY)**

Head, Onco-Dermatology, Hamburg University

Diagnosis and differential diagnosis of Melanoma as precondition for adequate therapy

15:30-16:00 **TREVES A, PhD (ISRAEL)**

Melanoma Center, Sheba Medical Center, Tel Aviv

Cell therapies: from regenerative medicine to Cancer Immunology


16:00-16:30 **BARAK V, PhD (ISRAEL)**

Head, Immunology Lab for Tumor Diagnosis,
Hadassah -University Medical Center, Jerusalem

Biomarkers for assessment of response to new therapies in Melanoma

16:30 - 17:00 **COFFEE, POSTERS, EXHIBITION**

17:00-19:00 **POSTERS GUIDED SESSION**



SESSION: PROSTATE CANCER 2

CHAIRS: SEMJONOW A (GERMANY) KUCERA R (CZECH REP.)

- 08:30-09:00 SEMJONOW A, MD (GERMANY)**
Vice Chair, Prostate Center, University Hospital, Münster
Growing evidence in Prostate Cancer screening emphasizes the need for active surveillance
- 09:00-09:30 CARSTEN S, MD (GERMANY)**
Urology Clinic, Charité University Hospital, Berlin
Prostate Cancer Biomarkers: PHI - a new marker
- 09:30-09:45 VESELI S, MD (CZECH REP)**
Urology, Charles University 2nd Faculty of Medicine, University Hospital Motol, Prague.
Prostate Health Index Predicts Clinically Significant Prostate Cancer in Final Pathology after Surgical Treatment
- 09:45-10:00 HOLUBECK L, MD, PhD (CZECH REP.)**
Clinical Oncology Dep, Na Homolce Hospital, Prague
Benefit of AV-R7 as treatment selection Marker in patients with metastatic castrationresistant Prostate Cancer
- 10:00-10:30 MAKRANZ C, MD (ISRAEL)**
Neuro-Oncology Dep., Hadassah University Medical Center, Jerusalem
Brain-derived circulating DNA as a Biomarker for Radiotherapy-induced brain damage
- 10:30 -11:00 COFFEE, POSTERS, EXHIBITION**

SESSION: LUNG CANCER

CHAIRS: MOLINA R (SPAIN) NECHUSHTAN H (ISRAEL)

08:30-09:00 **NECHUSHTAN H, MD, PhD (ISRAEL)**

Head, Lung Cancer Unit, Hadassah -University Medical Center, Jerusalem.

New combined therapies for Lung Cancer.

09:00-09:30 **MOLINA R, MD, PhD (SPAIN)**

Head, Laboratory Hospital Clinic, Oncobiology Unit, University of Barcelona

Tumor Markers Algorithm helping in the diagnosis / histological diagnosis of Lung Cancer- results of a multicentric study

09:30-10:00 **HOLDENRIEDER S, MD, PhD (GERMANY)**

Head, Institute of Laboratory Medicine, German Heart Center, Technical University, Munich

Multi parametric approaches for diagnosis and monitoring of Lung Cancer

10:00-10:30 **CREE I, PhD (UK)**

International Agency for Research on Cancer (IARC), World Health Organization

Standart for Pathologists: the WHO classification of Tumors

10:30 -11:00 **COFFEE, POSTERS, EXHIBITION**

SESSION: BIOBANKING

CHAIRS: **ZATLOUKAL K (AUSTRIA)** **BROCHAUSEN C (GERMANY)**

- 11:00-11:30** **ZATLOUKAL K, MD, PhD (AUSTRIA)**
Head, European Biobanking Society, MED CAMPUS, Gratz
Pre-analytical standards for Biobanking and Biomarker development
- 11:30-12:00** **BECKER K, MD (GERMANY)**
Technical University, Pathology Department, Munich
A Biobanker's view on protein analysis in Clinical tissues
- 12:00-12:30** **BROCHAUSEN C, MD, PhD (GERMANY)**
Institute of Pathology, University Regensburg, Regensburg.
BROTHER - a unique Bavarian - Czech cooperation to overcome hurdles for Biobank cooperation
- 12:30-13:00** **KINKOROVA J, PhD (CZECH REP.)**
Department of Immunochemistry, University Hospital Plzen.
Biobanking - an important tool for Cancer research
- 13:00 - 13:45** **LUNCH**

KEY NOTE LECTURE

- 13:45 - 14:30** **LETOURNEAU C, MD, PhD (FRANCE)**
Head, Department of Drug Development and Innovation, Institute Curie, Paris & Saint-Cloud
Precision Medicine in Oncology

SESSION: LUNG CANCER

CHAIRS: **MOLINA R (SPAIN)** **NECHUSHTAN H (ISRAEL)**

11:00-11:30 **AGUR Z, PhD (ISRAEL)**

OPTIMATA LTD, and Institute for Medical BioMathematics

A New Algorithm Predicting Imminent Disease Progression in Advanced Non-Small cell Lung Cancer Patients by Applying Machine- Learning to Multiple Tumor Markers

11:30-12:00 **ROSSUM V H, MD (HOLLAND)**

Department of Laboratory Medicine, The Netherlands Cancer Institute

Design of biomarker-response based medical test for early prediction of Nivolumab non-responsiveness in metastatic Non-Small Cell Lung Cancer patients

12:00-12:30 **DIETEL M, MD (GERMANY)**

Head, Pathology Department, Charite University, Berlin.


Predictive molecular Pathology

12:30-13:00 **HOLDENRIEDER S, MD, (GERMANY)**

Head , Institute of Laboratory Medicine, German Heart Center, Technical University, Munich

Meta-analysis on the relevance of CYFRA 21-1 and CEA for the assessment of therapy response in non-small cell lung cancer

13:00 -13:45 **LUNCH**



SESSION: LYMPHOMA, LEUKEMIA, MM

CHAIRS: **CHAPMAN C (UK)** **STIGBRAND T (SWEDEN)**

14:30-15:00 **LOOIJENGA L, PhD (HOLLAND)**

Pathology Dep., Erasmus MC, Rotterdam, Zuid Holland.

Identification and application of (molecular) biomarkers in patients with human Germ Cell Tumors

15:00-15:15 **ERIKSSON S, PhD (SWEDEN)**

AroCell AB, Uppsala

TK-210, a new marker for Lymphoma, Leukemia and MM

15:15-15:30 **PRADHAN T, PhD (INDIA)**

Cancer Research Program 4, Rajiv Gandhi Center for Biotechnology, Trivandrum, Kerala.

Role of the STIL gene in Colorectal Cancer Stem Cells

15:30 -16:00 **NOVAK V, MD (CZECH REP.)**

Urology, Charles University, 2nd Faculty of Medicine University Hospital Motol, Prague.

The Level of Serum Thymidine Kinase 1 Correlates with the Presence of Prostate Cancer.

16:00-16:30 **CLOSING CEREMONY AND AWARDS**

16:30 -17:00 **COFFEE, POSTERS, EXHIBITION**

THANKS TO OUR SPONSORS

International Agency for Research on Cancer



World Health
Organization

Cancer Research for Cancer Prevention

MAMMATYPER®

Innovation for your breast cancer diagnostics



molecular diagnostic test for quantitative determination of breast cancer biomarkers ER, PR, HER2, Ki-67 for any laboratory.

- Reliable and reproducible subtyping acc. to St Gallen¹
- Outperforms IHC by Ki-67 assessment²
- Extended information for patient's prognosis³
- From FFPE sample to result within 6 hours

For further information please
contact us or visit our website:
E-mail: service@biotechdiagnostics.de
Tel: +49 631 9084 2001

BIONTECH
Diagnostics

www.mammatyper.com

¹Gallagher et al., Annals of Oncology, 2013, 24(10):2507-2513

²Wolter et al., Breast Cancer Res Treat, 2011, 127(2):271-278

eBioControl
The eBioControl System

You wish to create and manage your Biobank? eBioControl® will support you with a highly flexible and intuitive software solution. Any material can be registered, administered and stored.

**Each Biobank is unique - eBioControl® adapts to your requirements.
Not vice versa.**

Handling the biobank samples is clearly arranged. Various materials may be assigned to different categories. The sample information required for each category are displayed customized. Sample listings can be prepared according to customized requests. These requests may then be stored and flexibly modified.

All these activities are secured based on a freely adjustable user administration. All actions of the samples and deposits will be illustrated user-related by the Audit Trail. The documentation is in accordance with the demands of GdP and DSGVO (GDPR) Part 1.1.

The current storage capacity will be displayed and can be seamlessly and unlimitedly extended. Samples can be marked with clear names, ID- resp. 3D-barcodes as well as RFID.

Advantages of eBioControl:

- Combination of different data
- Knowledge management
- Processing of any kind of sample
- Safe documentation of all sample movements
- Individual & graphical illustration of the storage capacity
- Unlimited number of samples or sample categories
- Scalably extendable with new storage systems
- GdP-conforms, Audit Trail



GEFAT - IT GmbH
Bismarckstr. 41
D-21484 Heesbeen (Ostfriesland)

www.gefat-it.de
Telefon: +49 5102 147150-0
Telefax: +49 5102 147150-99



Abbott

AWARD

BIONTECH

Diagnostics



GEFAT-IT

GMBH

Hamburg:

- local transportation:

<https://www.hvv.de/en>

- appropriate connections and prices:

<https://geofox.hvv.de/jsf/home>.

- the highlights of the month in Hamburg
(including Christmas markets):

[https://www.hamburg.com/explore/
events/highlights-of-the-month/](https://www.hamburg.com/explore/events/highlights-of-the-month/)



Tumor Biology

The Official Journal of the
International Society of Oncology and
BioMarkers (ISOBM)



Tumor Biology is a peer-reviewed, open access journal, which focusses on experimental and clinical cancer research.

Tumor Biology covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression.

When you publish in **Tumor Biology**, you will benefit from:

- Indexed by PubMed: MEDLINE
- Rapid but rigorous peer review, and quick decision times
- Open access dissemination of your article if accepted after peer review and upon payment of an article processing charge (APC) of 1,500 USD
- Authors retain copyright under a Creative Commons license

journals.sagepub.com/home/tub

 **SAGE openaccess**

Dear Colleagues,

I am honored to have been chosen as the new Editor-in-Chief of Tumor Biology. Much has changed since the Journal was launched in 1980. Initially known under the name of Oncodevelopmental Biology and Medicine, it is the official journal of The International Society of Oncology and Biomarkers (ISOBM), founded by scientists researching the proteins involved in embryonic development as tumor markers. These included Dr. Gary Abelev, who discovered alpha-fetoprotein (AFP) and Dr. Phil Gold, who discovered carcinoembryonic antigen (CEA). Over the years, following major developments in experimental and clinical cancer research, the scope of the journal has broadened, and Tumor Biology had become one of the largest (in terms of the number of publications) in the field of tumor biology.

I would like to acknowledge the support and cooperation of our new publisher. When SAGE Publishing took over in January 2017 Tumor Biology became fully open access, so that the articles are now readily available to the research community.

We also have a distinguished Editorial Board, including internationally recognized opinion leaders.

I would also like to express my gratitude to my predecessor, Professor Torgny Stigbrand, who has been fully committed to the journal for 17 years and significantly developed the journal.

My vision for Tumor Biology is to maintain and enhance its important position as a cancer research journal, publishing high-quality articles, significant and interesting for tumor biology scientists, diagnosticians and oncologists worldwide.

To achieve this objective, I will continue to focus on tumor markers/molecular biomarkers, mechanisms of tumor development and progression, and tumor targeting. I will also welcome translational cancer research studies, hot-topic reviews, and inspiring commentaries, including controversies, current research trends and future developments in the field. I will also welcome guidelines for the use of tumor markers. Special issues around significant, high-profile topics and conference proceedings will also be published.

Tumor Biology, while aiming for rapid publishing decisions, runs a rigorous review process, and gives particular attention to ethical issues such as plagiarism, self-plagiarism and conflicts of interest. All papers are reviewed by independent reviewers only, to provide accurate evaluations.

I would like to encourage all prospective authors to submit manuscripts to Tumor Biology.

The Editorial Board, SAGE Publishing and the authors are working together on developing the journal for the benefit of the research community.

Magdalena Chechlińska
Editor-in-Chief